About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Panel Rejects New Obesity Drug

by VR Sreeraman on July 16, 2010 at 11:57 AM
Font : A-A+

 FDA Panel Rejects New Obesity Drug

A panel of experts advising the US Food and Drug Administration voted Thursday against approving for sale a new obesity treatment called Qnexa, citing safety risks.

The FDA is not required to follow the recommendation of the expert panel on endocrinological and metabolic drugs, but generally accepts its findings.

Advertisement

Qnexa, made by California-based biotech firm Vivus, is the first obesity drug submitted to the FDA in a decade.

While a high percentage of Americans are overweight or obese, there are few medical treatments, and those on the market can have side effects including increased heart problems and intestinal gas.
Advertisement

Leland Wilson, chief executive officer at Vivus, said the company was still optimistic it would win final approval for Qnexa.

"We are disappointed with the advisory committee's vote," he said in a statement.

"While the final vote was close, and we are encouraged that the committee recognized the efficacy demonstrated in the Qnexa clinical trials, we will work closely with the FDA leading up to our October 28, 2010 (decision) date to address the labeling and safety questions raised during today's proceedings. We remain committed to patients living with obesity and weight-related disease."

Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Disability Day 2022 - The Role of Innovative Transformation
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Bariatric Surgery Drug Toxicity Obesity Bulimia Nervosa Body Mass Index Signature Drug Toxicity Liposuction Battle of the Bulge Diabesity Hunger Fullness and Weight Control 

Most Popular on Medindia

Drug Interaction Checker Blood Pressure Calculator Iron Intake Calculator Drug - Food Interactions Selfie Addiction Calculator Color Blindness Calculator Blood - Sugar Chart Drug Side Effects Calculator A-Z Drug Brands in India Sinopril (2mg) (Lacidipine)
open close
CONSULT ONLINE WITH A DOCTOR

×

FDA Panel Rejects New Obesity Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests